Recombinant Pig Endoglin (ENG)

What is pig endoglin and how does it compare to human endoglin?

Pig endoglin (ENG), also known as CD105, is a vascular endothelium glycoprotein that plays crucial roles in angiogenesis regulation and cardiovascular development. Structurally, porcine endoglin shares significant homology with human endoglin, containing an extracellular domain with a zona pellucida region that constitutes more than 30% of the extracellular portion . While human endoglin contains an arginine-glycine-aspartic acid (RGD) tripeptide at Arg399–Asp401 that may be involved in cell adhesion, this sequence is not conserved in pigs and other species . Both human and porcine endoglin function as TGF-beta coreceptors involved in signaling cascades that activate SMAD transcription factors, regulating vascular development and homeostasis .

What are the primary functions of endoglin in vascular biology?

Endoglin serves multiple critical functions in vascular biology:

• Regulation of angiogenesis and vascular remodeling

• Maintenance of vascular integrity and structure

• Modulation of endothelial cell migration

• Regulation of nitric oxide generation through interaction with endothelial nitric oxide synthase (eNOS)

• Mediation of TGF-β/BMP signaling cascades

• Regulation of cardiac remodeling in heart failure and myocardial infarction

Studies with endoglin heterozygous (Eng+/−) mice have demonstrated reduced levels of eNOS, resulting in decreased nitric oxide generation and increased eNOS-derived superoxide production due to uncoupling of eNOS activity . Endoglin also regulates vascular homeostasis through its colocalization to endothelial membrane-associated caveolae .

What expression systems are most effective for producing recombinant pig endoglin?

The most effective expression systems for recombinant pig endoglin production include:

• Mammalian cell systems: CHO or HEK293 cells provide appropriate post-translational modifications, particularly for glycosylation which accounts for approximately 30% of endoglin's molecular weight .

• Viral vector systems: Adenoviral-mediated expression systems have successfully produced recombinant human soluble endoglin, which can be adapted for porcine endoglin .

When selecting an expression system, researchers should consider that proper glycosylation is critical for endoglin's function, as the extracellular domain contains consensus motifs for several O-linked and N-linked oligosaccharide chains . The most efficient approach combines optimization of codon usage for the host system with inclusion of appropriate secretion signals for extracellular domain expression.

What purification methods yield the highest purity recombinant pig endoglin?

High-purity recombinant pig endoglin can be obtained through a multi-step purification process:

• Initial capture using affinity chromatography (anti-endoglin antibodies like MEM-229 or His-tag affinity if a tag was incorporated)

• Intermediate purification using ion exchange chromatography

• Polishing step utilizing size exclusion chromatography to remove aggregates and impurities

For immunological studies, it's critical to ensure endotoxin removal using polymyxin B columns or similar techniques. Quality control should include SDS-PAGE, Western blotting with specific antibodies such as MEM-229 , and functional assays to verify the binding capacity to TGF-β family ligands.

How is recombinant pig endoglin utilized in cancer immunotherapy research?

Recombinant pig endoglin has shown promising applications in cancer immunotherapy, particularly in combination vaccination strategies. Research has demonstrated that:

• Combination of endoglin DNA and recombinant protein vaccines enhances both protective and therapeutic anti-tumor efficacy in colon carcinoma and Lewis lung carcinoma models .

• This combination approach significantly induces IFN-γ secreting cells and produces higher titers of autoantibodies against endoglin that persist longer than either DNA or protein vaccination alone .

• The vaccination strategy results in CTL responses against endoglin-positive HUVECs but not against endoglin-negative tumor cells .

• Significant inhibition of tumor angiogenesis has been observed in tumor tissues following combination vaccination .

The methodological approach involves priming with endoglin plasmid DNA and boosting with recombinant protein, simultaneously leveraging both vaccination strategies to produce a superior immune response compared to single-modality approaches .

What role does recombinant pig endoglin play in xenotransplantation research?

Recombinant pig endoglin serves as an important tool in xenotransplantation research, particularly when investigating endothelial cell compatibility between porcine and human systems. Key applications include:

• In vitro compatibility testing: Recombinant pig endoglin helps evaluate human immune responses to porcine endothelial cells, providing an efficient method to identify ideal genetic modifications for improving pig-to-human compatibility .

• Genetic engineering assessment: When used in conjunction with genetically modified porcine endothelial cell lines, recombinant endoglin helps assess the impact of gene knockouts (such as GGTA1, CMAH, β4galNT2, SLA-I α chain, and β2-microglobulin) on xenoantigenicity .

• Validation of transgenic modifications: Researchers use recombinant pig endoglin to validate the function of human complement-regulating proteins (hCRPs) introduced into pigs, such as decay-acceleration factor (CD55), membrane cofactor protein (CD46), and membrane inhibitor of reactive lysis (CD59) .

This approach provides a more efficient alternative to direct nonhuman primate testing, allowing rapid screening of various genetic modifications before proceeding to more complex in vivo xenotransplantation studies .

What are the optimal isolation and culture conditions for porcine endothelial cells expressing endogenous endoglin?

Successful isolation and culture of porcine endothelial cells expressing endogenous endoglin requires careful attention to several critical factors, as shown in the research data below:

Based on research data, PBMCs from approximately 20% of pigs (7 out of 35) and 18% of individual batches processed (10 out of 57) successfully differentiated into cobblestone-forming colonies indicative of endothelial differentiation . The first colonies typically appear after 10.3 ± 2.1 days, though in some cases they may appear earlier (between days 7-9) .

What methods can verify the functional activity of recombinant pig endoglin?

To verify the functional activity of recombinant pig endoglin, researchers should employ multiple complementary approaches:

• TGF-β binding assays: Assess the protein's ability to bind TGF-β family ligands using ELISA or surface plasmon resonance.

• SMAD phosphorylation analysis: Measure the activation of SMAD1/5/8 (for BMP9 signaling) or SMAD2/3 (for TGF-β1 signaling) in endothelial cells treated with the recombinant protein .

• Endothelial cell migration assays: Evaluate the protein's ability to regulate endothelial cell migration in wound healing or Boyden chamber assays, as endoglin has been shown to regulate this process .

• Angiogenesis inhibition assessment: In xenograft models, measure the protein's ability to inhibit tumor angiogenesis by quantifying microvessel density in tumor tissues .

• Flow cytometry verification: Confirm protein recognition by specific antibodies such as MEM-229, which has been validated for recognition of porcine endoglin .

A comprehensive validation should incorporate multiple assays to verify both structural integrity and signaling capability of the recombinant protein.

How should researchers address variability in porcine endothelial-like cell derivation experiments?

The substantial variability observed in porcine endothelial-like cell derivation (with success rates of only 18-20%) requires systematic analysis and mitigation strategies:

• Standardize critical parameters: Implement strict standardization of blood collection, transport time (<30 minutes), centrifugation protocols (10-12 minutes), and culture media composition based on successful isolations.

• Statistical power calculations: Design experiments with sufficient replicates to account for the expected 80% failure rate, using power analysis to determine appropriate sample sizes.

• Multivariate analysis: Apply principal component analysis or multiple regression to identify combinations of factors that predict successful isolation. The research data suggests that multiple parameters interact in complex ways that affect outcomes .

• Control charts: Implement Shewhart control charts to monitor process stability and identify special cause variation in the isolation process.

• Donor stratification: Consider stratifying pigs by age, weight, and health status, as these factors may influence the yield and quality of endothelial progenitor cells.

When reporting results, researchers should provide detailed methods and comprehensive tables similar to those in the original research , specifying all procedural variables to facilitate reproducibility and meta-analysis across studies.

What statistical approaches are most appropriate for analyzing xenoreactivity data with recombinant pig endoglin?

When analyzing xenoreactivity data involving recombinant pig endoglin, researchers should employ these statistical approaches:

• Mixed-effects models: Account for both fixed effects (genetic modifications, treatment conditions) and random effects (donor variability, experimental batch) when assessing human immune responses to porcine endothelial cells .

• Repeated measures ANOVA: Appropriate for time-course experiments evaluating antibody titers or cellular responses to recombinant pig endoglin over time .

• Survival analysis: Use Kaplan-Meier curves and Cox proportional hazards models when analyzing xenograft rejection times in animal models.

• Non-parametric tests: Consider Wilcoxon rank-sum or Kruskal-Wallis tests when data violates normality assumptions, which is common with biological variability in xenoreactivity.

• Multiple testing correction: Apply Benjamini-Hochberg or similar procedures when conducting multiple comparisons to control false discovery rates.

When presenting results, researchers should include effect sizes and confidence intervals alongside p-values to provide a complete picture of statistical significance and biological relevance.

How can CRISPR/Cas9 technology be optimized for modifying endoglin expression in porcine endothelial cells?

CRISPR/Cas9 technology offers powerful approaches for modifying endoglin expression in porcine endothelial cells, but requires specific optimization:

• Guide RNA design optimization: Select multiple gRNAs targeting different regions of the porcine endoglin gene and validate cutting efficiency in vitro before cellular application. For knockout studies, target early exons to ensure complete protein disruption.

• Delivery method selection: For primary porcine endothelial cells, nucleofection typically achieves higher efficiency than lipid-based transfection. For immortalized cell lines, lentiviral delivery of Cas9 and gRNA may provide more consistent results .

• Verification strategy: Implement a multi-tiered verification approach:

  • Genomic verification with T7E1 assay or targeted sequencing

  • Protein expression verification via Western blot and flow cytometry

  • Functional validation through TGF-β signaling assays

• Off-target analysis: Perform whole-genome sequencing on modified cell lines to identify potential off-target modifications, particularly in genes related to TGF-β signaling or vascular function.

Recent research on genetically modified porcine endothelial cells demonstrated successful sequential disruption of five genes including GGTA1, CMAH, β4galNT2, SLA-I α chain, and β2-microglobulin using CRISPR/Cas9 technology , providing a methodological framework that could be adapted for endoglin modification.

What are the potential mechanisms for the observed synergistic effect of combined endoglin DNA and protein vaccination?

Research has demonstrated a superior anti-tumor effect when combining endoglin DNA and protein vaccination compared to either approach alone . Several potential mechanisms may explain this synergy:

• Complementary immune activation: DNA vaccines primarily activate CD8+ T-cell responses through endogenous antigen processing and MHC I presentation, while protein vaccines favor CD4+ T-cell responses and antibody production through MHC II presentation. The combination activates both arms of the adaptive immune system simultaneously.

• Enhanced IFN-γ production: The combination vaccination significantly induces IFN-γ secreting cells , which may enhance antigen presentation, increase MHC expression, and promote a TH1-polarized immune response conducive to anti-tumor activity.

• Prolonged antibody persistence: Data shows that antibody levels against endoglin lasted longer in mice receiving the combined vaccination , suggesting that the DNA component may establish a reservoir of antigen-expressing cells that provide ongoing stimulation to maintain antibody production.

• CTL response specificity: The observed CTL response against endoglin-positive HUVECs but not endoglin-negative tumor cells suggests that the vaccination strategy induces highly specific immune responses targeting the tumor vasculature rather than tumor cells directly.

Researchers investigating this phenomenon should design experiments that separate these potential mechanisms, perhaps by depleting specific immune cell populations or neutralizing key cytokines to determine their relative contributions to the observed synergy.

How can researchers overcome poor expression yields of recombinant pig endoglin?

When encountering poor expression yields of recombinant pig endoglin, researchers should implement this systematic troubleshooting approach:

• Codon optimization: Analyze and optimize codon usage for the expression system being used, as sub-optimal codons can significantly reduce translation efficiency.

• Signal sequence modification: Test alternative signal sequences specific to the expression host to improve secretion efficiency, particularly important since endoglin contains approximately 30% glycosylation by weight .

• Expression construct design: Consider expressing only the extracellular domain (similar to soluble endoglin) rather than the full-length protein to improve folding and secretion efficiency.

• Host cell selection: Compare yields across multiple expression systems, including CHO, HEK293, and baculovirus-infected insect cells, as host-specific factors may impact expression.

• Culture condition optimization: Systematically test temperature modulation (30-37°C), specialized media formulations, and feeding strategies to identify optimal growth conditions for protein expression.

If partial protein degradation is observed, incorporate protease inhibitors in the culture media and harvest supernatant at earlier time points to mitigate proteolytic degradation during extended culture periods.

What approaches can address cross-reactivity issues when studying porcine endoglin in human systems?

Cross-reactivity issues between porcine and human systems present significant challenges in endoglin research. To address these challenges:

• Epitope mapping: Perform comprehensive epitope mapping of antibodies to identify regions of high homology versus divergence between porcine and human endoglin.

• Absorption controls: Pre-absorb antibodies with recombinant human endoglin before using them in assays with porcine samples to remove cross-reactive antibodies.

• Species-specific detection reagents: Develop and validate monoclonal antibodies specific to porcine-unique epitopes to ensure specificity in mixed-species contexts.

• Negative control cell lines: Generate endoglin-knockout cell lines through CRISPR/Cas9 editing to serve as rigorous negative controls that account for all potential cross-reactive epitopes.

• Sequential immunoprecipitation: In complex samples, perform sequential immunoprecipitation first with human-specific antibodies to deplete human endoglin, followed by porcine-specific antibodies to selectively capture porcine endoglin.

For in vitro studies evaluating human immune responses to porcine cells, careful controls with species-matched cells and proteins are essential to distinguish specific from non-specific interactions .